BioNotebook: Targacept gone in reverse merger with Catalyst, plus five other deals

After a string of failures, Winston-Salem, North Carolina-based Targacept and its neuronal nicotinic receptor (NNR) therapeutics will be replaced by engineered human proteases for hemophilia and complement-mediated disorders in a reverse merger with privately-held Catalyst Biosciences in South San Francisco.

After a string of failures, Winston-Salem, North Carolina-based Targacept and its neuronal nicotinic receptor (NNR) therapeutics will be replaced by engineered human proteases for hemophilia and complement-mediated disorders in a reverse merger with privately-held Catalyst Biosciences in South San Francisco.

Publicly-held Targacept will be known as Catalyst and its stock market ticker symbol will change from TRGT to CBIO. The...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Alimentary/Metabolic

More from Therapy Areas

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Obesity Beyond GLP-1s: Amylins – The Next Frontier

 
• By 

In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.